Torrent Pharmaceuticals plans non-convertible debentures (NCDs)

What happened

In a filing with the BSE on 9 November 2026 at 01:45 PM, Torrent Pharmaceuticals (TORNTPHARM) said that it has taken up non-convertible debentures (NCDs).

Company snapshot

Torrent Pharmaceuticals is a large-cap company in the Healthcare sector, with a market value of about ₹1.81 lakh crore.

The stock last traded at ₹4,762, against a 52-week range of ₹3,602–₹5,250 (9.3% below the high).

Before this filing the shares had moved +0.7% over the month and −3.5% over three months. Average daily turnover over the last 20 sessions was about ₹153 crore.

Promoters held 60.78% at the end of Q2 FY27. Foreign institutions owned 17.22% and domestic institutions 13.46%.

What history shows

BCEIE's records show 1 previous fund raising filing from the company since May 2026.

Across 33 similar disclosures by other Healthcare companies, shares moved +0.7% on average the next day and +0.8% over five days; 55% of them rose the next day.

Market-wide, 1,748 fund raising filings with an impact score of 50 or more saw an average next-day move of +0.3%, with 47% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• How the money raised is used and, for equity instruments, the dilution for existing shareholders.

In the news

Recent coverage elsewhere (links open the original publisher):

• TORNTPHARM Outlook for the Week — Equitypandit, 30 Oct 2026
• JBCHEPHARM: Revenue and profit rose 6–8% year-over-year, with integration into Torrent Pharmaceuticals progressing — TradingView, 7 Nov 2026
• Torrent Pharmaceuticals TORNTPHARM Q2 FY27 Earnings Call Transcript — Kalkine India, 29 Oct 2026
• Surge in Open Interest Signals Shifting Market Sentiment for Torrent Pharmaceuticals Ltd. — MarketsMojo, 6 Nov 2026
• Torrent Pharmaceuticals TORNTPHARM Investor Meets Nov 2026 — Kalkine India, 6 Nov 2026

Source

• Exchange filing (PDF)